N. Kawanishi

发表

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2010, Cell cycle.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo

H. Hirai, T. Shimomura, Makiko Kobayashi, 2011, Investigational New Drugs.

Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.

H. Hirai, N. Kawanishi, T. Sugimoto, 2006, Bioorganic & medicinal chemistry letters.

Expression levels of p 18 INK 4 C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009 .

Expression levels of p18 INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009 .

MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel

T. Shimomura, Koji Ichikawa, Shinichi Hasako, 2010, Molecular Cancer Therapeutics.

A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.

T Honma, K. Fukasawa, N. Kawanishi, 2001, Journal of medicinal chemistry.

Rearrangement of cis- and trans-2-Methyl-3-(substituted phenyl)-1,2,3,4-tetrahydroisoquinolinium 2-Methylides

N. Kawanishi, N. Shirai, K. Hatano, 1995 .

Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.

Hiroshi Hirai, H. Hirai, N. Kawanishi, 2005, Current topics in medicinal chemistry.

Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines

H. Hirai, T. Shimomura, T. Eguchi, 2009, Molecular Cancer Therapeutics.

Structure-activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines.

N. Kawanishi, T. Hayama, S. Ozaki, 2004, Bioorganic & medicinal chemistry letters.